Examination of the Effect of Self Monitoring on patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

INTERVENTION: Self Monitoring with PCIPN/ Regular care Self‐monitoring type (60 people, below intervention group) / knowledge provision type (60 people, control group) Self monitoring type with self‐monitoring type further self‐monitoring type (30 persons, the following record book group), smartphone application ), And intervention study is conducted according to the self‐monitoring conceptual model created.In both the control group and the intervention group, an interview was conducted on the start date, and peripheral nerves Do you understand lifestyle movements that do not cause numbness and pain due to obstacles, methods of massage and cold / hot menstruation, differences between acute symptoms and chronic symptoms, necessity of properly communicating the symptoms of peripheral neuropathy to medical personnel Confirm and provide supplementary explanation about missing knowledge. Three weeks, six weeks, and nine weeks later, peripheral nerve disorders and living conditions were also confirmed through interviews in both the control group and the intervention group, and the presence or absence of intervention and the perception of peripheral neuropathy by the teaching materials being used Change, coping exercises to understand changes in behaviors * 1st, 3rd, 4th: FACT‐G, SEAC, Peripheral Neuropathy Scale, Anxiety Scale, Safety Daily Behavior Checklist, Thermometers and Troublesome Thermometers * 2nd: FACT‐G, SEAC, Peripheral Neurological Disorder Scale, Anxiety Scale, Psychological and Heterostatic Thermometers CONDITION: Breast cancer, colon cancer, gynecological cancer PRIMARY OUTCOME: *The effect of self‐management education SECONDARY OUTCOME: *The Comprehensive Assessment Scale for Chemotherapy‐induced Peripheral Neuropathy in Survivors of Cancer(CAS‐CIPN); *Cancer‐chemotherapy Concerns Rating Scale(CCRS); *Improve self‐care capacity; *Improvement of QOL (FACT‐G); *Improvement of self‐efficacy (SEAC) INCLUSION CRITERIA: Patients with colon cancer, breast cancer, gynecological cancer who received compliance with outpatient regimen including platinum drug and taxane drug more than three times. Including patients without peripheral neuropathy